New strategies in the management of Guillain-Barré syndrome. (Q38140727)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

New strategies in the management of Guillain-Barré syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

main subject

Guillain–Barré syndrome

0 references

author

Junwei Hao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Jinting Xiao

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Alain R Simard

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Fu-Dong Shi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

1 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

Clinical Reviews in Allergy & Immunology

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

274-288

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24057598%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12016-013-8388-5

22 February 2020

exact match

0 references

cites work

Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Electrodiagnostic criteria for Guillain–Barrè syndrome: A critical revision and the need for an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Cardiovascular complications of the Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

21 January 2018

Guillain–Barré Syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Neurologic indications for therapeutic plasma exchange: 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Successful treatment of Guillain-Barré syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Guillain-Barré syndrome as presenting feature in a patient with lupus nephritis, with complete resolution after cyclophosphamide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Efficacy and tolerability of rituximab in patients with rhupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Autoimmune diseases of the peripheral nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Rituximab - shadow, illusion or light?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Rituximab-responsive Guillain-Barré syndrome following allogeneic hematopoietic SCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Acupuncture sensation during ultrasound guided acupuncture needling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Electro-acupuncture promotes differentiation of mesenchymal stem cells, regeneration of nerve fibers and partial functional recovery after spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

An experimental electro-acupuncture study in treatment of the rat demyelinated spinal cord injury induced by ethidium bromide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

The neuroimmune basis of anti-inflammatory acupuncture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Acupuncture and immune modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Male germ cell apoptosis and epigenetic histone modification induced by Tripterygium wilfordii Hook F

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5-hydroxytriptolide (LLDT-8)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Neurotrophin regulation of neural circuit development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Neurotrophic factors--a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

A NERVE GROWTH-STIMULATING FACTOR ISOLATED FROM SARCOM AS 37 AND 180.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

A small peptide mimetic of brain-derived neurotrophic factor promotes peripheral myelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Progesterone, brain-derived neurotrophic factor and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Brain-derived neurotrophic factor and obesity in the WAGR syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

The neurotrophins BDNF, NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Brain-derived neurotrophic factor in experimental autoimmune neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Hypermetabolism and hypercatabolism in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Inpatient management of guillain-barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Valproic acid improves outcome after rodent spinal cord injury: potential roles of histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Valproic acid attenuates inflammation in experimental autoimmune neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Pioglitazone, PPARγ agonist, attenuates experimental autoimmune neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Soluble TNFR1 inhibits the development of experimental autoimmune neuritis by modulating blood-nerve-barrier permeability and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Statins: mechanisms of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Mechanisms for the anti-inflammatory effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Statins in stroke prevention: what an internist should know

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Statins in the spectrum of neurologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Schwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Erythropoietin: still on the neuroprotection road

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

New approaches to neuroprotective drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Upregulation of erythropoietin in rat peripheral nervous system with experimental autoimmune neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-β in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Preventive effects of the anti-vasospasm agent via the regulation of the Rho-kinase pathway on the development of steroid-induced osteonecrosis in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Preventive and therapeutic effects of the selective Rho-kinase inhibitor fasudil on experimental autoimmune neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Suppression of experimental autoimmune neuritis by leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Inhibition of Ras attenuates the course of experimental autoimmune neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

APOE ε3 attenuates experimental autoimmune neuritis by modulating T cell, macrophage and Schwann cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-013-8388-5

Neuromuscular disease: IVIg for neuromuscular disease-effective but expensive

21 January 2018

1 reference

12 December 2020

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome

1 reference

12 December 2020

Plasma exchange for Guillain-Barré syndrome

1 reference

12 December 2020

Corticosteroids for Guillain-Barré syndrome

1 reference

12 December 2020

[Effect of Tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barre syndrome]

1 reference

12 December 2020

[CSF filtration and interferon-beta for Guillain-Barré syndrome]

1 reference

12 December 2020

Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy

1 reference

12 December 2020

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome

1 reference

12 December 2020

Tripterugium wilfordii multiglucoside-treated case of sensory perineuritis

1 reference

12 December 2020

Preventive and curative effects of cyclophosphamide in an animal model of Guillain Barrè syndrome

1 reference

12 December 2020

Lovastatin attenuates nerve injury in an animal model of Guillain-Barré syndrome

1 reference

12 December 2020

The effect of treatment with crotapotin on the evolution of experimental autoimmune neuritis induced in Lewis rats

1 reference

12 December 2020

Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis

1 reference

12 December 2020

Treatment of Guillain-Barré syndrome with interferon-beta

1 reference

12 December 2020

Inhibition of experimental autoimmune neuritis by the immunomodulator linomide

1 reference

12 December 2020

Immunosuppressant triptolide inhibits dendritic cell-mediated chemoattraction of neutrophils and T cells through inhibiting Stat3 phosphorylation and NF-kappaB activation

1 reference

12 December 2020

Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen

1 reference

12 December 2020

Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barré syndrome

1 reference

12 December 2020

Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study

1 reference

12 December 2020

Efficacy of low-dose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain-Barre syndrome-like acute axonal neuropathies: report of two cases

1 reference

12 December 2020

Acute and chronic demyelinating inflammatory polyradiculoneuropathy. Association with autoimmune diseases and lymphocyte response to human neuritogenic protein

1 reference

12 December 2020

Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies

1 reference

12 December 2020

Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial

1 reference

12 December 2020

Mycophenolate mofetil in animal models of autoimmune disease

1 reference

12 December 2020

Antigen-specific immunosuppression: nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats

1 reference

12 December 2020

Corticosteroids for Guillain-Barré syndrome

1 reference

12 December 2020

Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation

1 reference

12 December 2020

Intravenous immunoglobulin for Guillain-Barré syndrome

1 reference

12 December 2020

Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats

1 reference

12 December 2020

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome

1 reference

12 December 2020

Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis

1 reference

12 December 2020

Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis

1 reference

12 December 2020

Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

1 reference

12 December 2020

Treatment for Guillain-Barré syndrome

1 reference

12 December 2020